Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Marinus (DE:61Y)
STUTTGART:61Y
Marinus (61Y) Stock Price & Analysis
1 Followers
61Y Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.20 - €10.20
Previous Close€1.29
Volume0.00
Average Volume (3M)553.00
Market Cap
€71.73M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
Beta0.43
Next Earnings
May 09, 2024EPS Estimate
-€0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume553
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.84Price Target Upside663.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Marinus News
Bulls Say, Bears Say
Bulls Say
Acquisition PotentialThe company could still be an attractive acquisition target, potentially leading to a higher valuation.
Clinical Trial ProgressAn independent data committee recommended the continuation of the trial, indicating positive progress.
Market OpportunitySignificant market opportunity anticipated for Marinus, with commercial potential exceeding $600M.
Bears Say
Clinical Trial ResultsPhase 3 RAISE study of ganaxolone in refractory status epilepticus did not meet the pre-defined stopping criteria at the interim analysis, casting doubts on the drug's efficacy.
Company's Financial HealthMarinus is reviewing cost-cutting measures to support their cash balance due to a bleak future for IV ganaxolone, signaling concerns over the company's financial stability.
Financial ForecastAnalyst lowers the risk-adjusted, DCF-derived price target from $15 to $12, reflecting significantly reduced expectations for the commercial success of IV ganaxolone.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.60% Other Institutional Investors
99.40% Public Companies and
Individual Investors
61Y FAQ
What was Marinus’s price range in the past 12 months?
Marinus lowest stock price was €1.20 and its highest was €10.20 in the past 12 months.
What is Marinus’s market cap?
Currently, no data Available
When is Marinus’s upcoming earnings report date?
Marinus’s upcoming earnings report date is May 09, 2024 which is in 10 days.
How were Marinus’s earnings last quarter?
Marinus released its earnings results on Mar 05, 2024. The company reported -€0.691 earnings per share for the quarter, missing the consensus estimate of -€0.582 by -€0.109.
Is Marinus overvalued?
According to Wall Street analysts Marinus’s price is currently Undervalued.
Does Marinus pay dividends?
Marinus does not currently pay dividends.
What is Marinus’s EPS estimate?
Marinus’s EPS estimate is -€0.62.
How many shares outstanding does Marinus have?
Currently, no data Available
What happened to Marinus’s price movement after its last earnings report?
Marinus reported an EPS of -€0.691 in its last earnings report, missing expectations of -€0.582. Following the earnings report the stock price went down -3.889%.
Which hedge fund is a major shareholder of Marinus?
Among the largest hedge funds holding Marinus’s share is GMT Capital Corp. It holds Marinus’s shares valued at 19M.
---
Marinus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€9.84 (663.11% Upside)
€9.84 (663.11% Upside)
Blogger Sentiment
Bullish
DE:61Y Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $214.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.03%
12-Months-Change
Fundamentals
Return on Equity
-213.02%
Trailing 12-Months
Asset Growth
-34.14%
Trailing 12-Months
Company Description
Marinus
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.
---
61Y Earnings Call
Q4 2024
0:00 / 0:00
---
61Y Stock 12 Months Forecast
Average Price Target
€9.84
▲(663.11% Upside)
Technical Analysis
Best Analysts Covering 61Y
1 Year
1 Year Success Rate
16/34 ratings generated profit
1 Year Average Return
+6.14%
reiterated a buy rating 14 days ago
Copying Michael Higgins's trades and holding each position for 1 Year would result in 47.06% of your transactions generating a profit, with an average return of +6.14% per trade.
---